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Background: The clinical effectiveness of inhaled tobramycin depends on the dose reaching the desired regions of the lungs. This study evaluates
the inﬂuence of breathing mode on tobramycin lung deposition using its pharmacokinetics as surrogate for deposition.
Methods: In a randomized, open-label, crossover study lung deposition in 18 adult CF patients is evaluated following inhalation of tobramycin
aerosol using the I-neb nebulizer with TBM (Tidal Breathing Mode) and TIM (Target Inhalation Mode) breathing patterns. Breathing in TIM
forced the patient to inhale in a slow and deep manner. Patients were categorized in three subgroups according to their lung function: ≤59%, 60–
79% or ≥80% of FEV1 predicted. Blood samples were collected in order to model tobramycin pharmacokinetics. Nebulization time was recorded.
Results: Inhalation with TIM resulted in signiﬁcantly higher maximum serum levels and area under the concentration–time curves (0–24 h). Mean
bioavailability of TIM relative to TBM was 1.53 ± 0.41. Mean nebulization time was reduced by half with TIM. Subgroup category did not affect
the results.
Conclusions: Slow and deep inhalation of aerosolized tobramycin resulted in higher lung deposition and shorter nebulization time compared to
tidal breathing, regardless of the disease severity of the CF patient.
Dutch trial register number NTR3109.
© 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Aerosol; Tobramycin; Lung deposition; Breathing mode; Inhalation; Pharmacokinetics1. Introduction
Pulmonary complications are responsible for the majority of
morbidity and virtually all mortality in cystic fibrosis (CF) [1]. Due
to increased mucus viscosity in the respiratory tract mucociliary
clearance is impaired and the lungs become colonized and infected
with bacteria, of which Pseudomonas aeruginosa (Pa) is the most⁎ Corresponding author at: HagaZiekenhuis, locatie Leyweg, Ziekenhuisapotheek,
e etage, Leyweg 275, 2545 CHDen Haag, The Netherlands. Tel.: +31 70 2101205.
E-mail address: a.vanvelzen@hagaziekenhuis.nl (A.J. van Velzen).
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1569-1993/© 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. Aimportant pathogen in CF lung disease [2]. Tobramycin inhalation
is one of the antibiotics recommended in the treatment of chronic
Pa infection in patients with CF [3].
The clinical effectiveness of inhaled antibiotics depends on the
dose reaching the desired regions of the lungs. Pa is present in
both the large and small airways. Yet a high peripheral deposition
seems desirable because of the exponentially increasing surface
area from the central lung towards the alveoli [4]. Inhalation of
aerosols with a mass median aerodynamic diameter of 2–3 μm in
combination with a slow deep breathing pattern has been found to
result in optimal peripheral deposition [5]. However, tobramycin
is licensed to be administered with a less efficient jet nebulizerll rights reserved.
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breathing and highly variable particle size distributions. More
efficient and breath-controlled nebulizers have been developed in
recent years, such as the I-neb nebulizer [6]. The I-neb can deliver
homogenously-sized aerosols within the respirable range with
two different breathing patterns: Tidal Breathing Mode (TBM)
and Target Inhalation Mode (TIM). A recent crossover imaging
study of 12 healthy subjects inhaling radiolabeled saline showed
that lung deposition was significantly higher and nebulization
time was shorter for TIM compared to TBM [7]. To our
knowledge no randomized deposition studies with the I-neb have
been carried out in CF patients.
It is possible that the benefits of current inhaled antibiotics in
CF could be enhanced by targeting the peripheral airways using
a slow and deep breathing mode during inhalation. The aim of
this study was to compare deposition of aerosolized tobramycin
delivered with the I-neb nebulizer between TIM and TBM
breathing patterns in CF patients with different disease severity,
using tobramycin pharmacokinetics as surrogate for lung
deposition. Disease severity of the individual patient may be
an important determinant, since inter-patient variability in lung
deposition is known to be large in CF patients [8].2. Methods
2.1. Study population
The study was performed in the Centre for Cystic Fibrosis,
Haga Teaching Hospital, The Hague, The Netherlands. Patients
aged 18 years or older and with a confirmed diagnosis of CF
(genetic analysis) were eligible for this study. Acute exacerba-
tion of pulmonary infection, intravenous use of tobramycin within
7 days prior to or during the study visits, impaired renal function
(estimated glomerular filtration rate (eGFR) b 60 mL/min), use
of loop diuretics and pregnancy or lactation were the exclusion
criteria. According to their lung function, patients were categorized
in subgroup 1, 2 or 3 corresponding to FEV1 (forced expiratory
volume in the first second) predicted ≤59%, 60–79% or ≥80%,
respectively. Each subgroup contained 6 patients.
The study was approved by the local ethics committee
(METC Zuidwest Holland, The Netherlands) and the Central
Committee on Research Involving Human Subjects (CCMO
The Hague, The Netherlands) and was conducted in accordance
with the principles of the Declaration of Helsinki and Good
Clinical Practice. Full informed written consent was obtained
from all patients.2.2. Study design
In a randomized, open-label, crossover study lung deposi-
tion in 18 adult CF patients is evaluated following tobramycin
inhalation using the I-neb nebulizer with TBM (Tidal Breathing
Mode) and TIM (Target Inhalation Mode) breathing patterns.
An off-label tobramycin solution and drug–device combination
was used to assess the effect of breathing mode on aerosol lung
deposition.The study consisted of two visits for tobramycin inhalation,
once with TBM and the other time with TIM, in random order and
separated by a week washout. On both days patients received a
physical examination, kidney function (eGFR) was established and
spirometry (Jaeger Masterscreen PFT, CareFusion, Hoechberg,
Germany) was performed according to the ATS/ERS guidelines
[9]. Blood samples were collected for tobramycin analysis. Venous
blood samples were taken in the hospital before and 15, 30 and
60 min after the start of each inhalation. Dried blood spots were
collected by patients themselves at home 3, 4, 6 and 24 h after
inhalation [10].
2.3. Inhalation procedure
Tobramycin was administered with the I-neb AAD system
(Philips, Respironics, Chichester, United Kingdom) in combi-
nation with a white 1 mL medication chamber. This nebulizer
combines Adaptive Aerosol Delivery (AAD) with Vibrating
Mesh Technology (VMT). In AAD the nebulizer monitors and
adapts to the individual breathing pattern and medication is
only delivered during inhalation [6]. With VMT the liquid
medication is moved through a perforated metal mesh (2 μm) in
order to create particles of a similar size [6]. The nebulizer can
deliver aerosols with two different breathing patterns: TBM and
TIM. In TBM the patient inhales during spontaneous tidal
breathing and aerosols are pulsed during the first 50–80% of this
inhalation [11]. With TIM the inspiratory flow is limited to
approximately 20 L/min by a built-in resistance in the mouth-
piece, which guides the patient to perform a slow and deep
inhalation. Aerosols are pulsed during the complete extended
inhalation except for the last second, in order to ensure sufficient
time for pulmonary deposition [11]. Patients were all I-neb naive
users and were trained in each breathing pattern prior to dosing.
No active compound was inhaled during these training sessions.
Subsequently, patients nebulized 1 mL of an ~10% tobramycin
(as sulfate) solution with both breathing modes. Nebulization
time was recorded.
2.4. Tobramycin analysis
Tobramycin sulfate (Spruyt Hillen, IJsselstein, The Nether-
lands) was dissolved in water for injection. A fresh solution was
prepared for each patient under aseptic conditions, which was used
for both study visits. Previous studies have shown that a device
dose of 100 mg is sufficient to measure serum concentrations and
that a 10% tobramycin inhalation solution is well tolerated [12,13].
The exact tobramycin concentration of each solution was
measured before inhalation. After inhalation, the I-neb device,
mouthpiece, medication chamber and exhalation filter (added to
the standard device) were rinsed with sodium chloride 0.9%
and the residual amount of tobramycin in the rinsing solutions
was also measured. The net inhaled dose was calculated for
each patient at each study visit. Tobramycin was measured
in all blood samples with high-performance liquid chromatog-
raphy (HPLC)–tandem mass spectrometry (MS/MS) [14]. The
lower limit of quantification (LLOQ) was 0.1 mg/L with a
coefficient of variation of b2.2%. The MULTIGEN tobramycin
Table 1
Patient characteristics and inhaled dose.
Study population n = 18
Subgroup n = 6
TIM TBM P-value a
eGFR (mL/min) study population 114.92 ± 23.74 119.20 ± 30.45 NS
Subgroup 1 112.00 ± 26.65 117.60 ± 34.62 NS
Subgroup 2 95.50 ± 34.65 106.83 ± 31.47 NS
Subgroup 3 123.83 ± 17.03 139.75 ± 14.32 NS
FEV1% predicted study
population
67.44 ± 20.48 68.83 ± 21.37 NS
Subgroup 1 46.67 ± 13.19 46.17 ± 12.12 NS
Subgroup 2 65.17 ± 5.81 67.67 ± 7.55 0.026
Subgroup 3 90.50 ± 7.50 92.67 ± 7.03 NS
Net inhaled dose (mg) study
population
71.77 ± 16.45 71.76 ± 13.15 NS
Subgroup 1 75.11 ± 15.21 73.29 ± 12.61 NS
Subgroup 2 58.48 ± 11.62 65.82 ± 16.00 NS
Subgroup 3 81.73 ± 14.44 76.18 ± 10.22 NS
Data are presented as mean ± sd. TIM = Target Inhalation Mode; TBM = Tidal
Breathing Mode; eGFR = estimated glomerular filtration rate based on the
Modification of Diet in Renal Disease (MDRD) equation; FEV1 = forced
expiratory volume in the first second; Subgroup 1 ≤ 59, 2 = 60–79, 3 ≥ 80
FEV1% predicted; NS = not statistically significant.
a P-values are calculated using paired t-tests.
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Diagnostics, Hoofddorp, The Netherlands) was used to
measure the amount of tobramycin in the I-neb rinse and
inhalation solution (LLOQ = 0.2 mg/L).
2.5. Pharmacokinetic analysis
Individual pharmacokinetic parameters of tobramycin inhala-
tion were calculated and assimilated with patient tobramycin serum
values using a computerized CF-based Bayesian two-compartment
open population pharmacokinetic model with first order absorption
and first order elimination from the central compartment
(MW-Pharm version 3.60, Mediware, Groningen, The Nether-
lands). The following parameters were calculated: maximum
serum level (Cmax), trough serum level (Ctrough), time to maximum
serum level (Tmax) and area under the concentration–time curve
(AUC0–24 h).
2.5.1. Main outcome measure
Bioavailability of aerosolized tobramycin, i.e., the fraction of
the inhaled dose available for absorption, can be used as surrogate
parameter for lung deposition, since tobramycin is not effectively
absorbed by the gastrointestinal tract [15–18]. Bioavailability (F)
of TIM relative to TBM (Frel) was calculated with the formula:
Frel = (AUC0–24 hTIM / AUC0–24 hTBM) × (DoseTBM / DoseTIM)
in which the Dose represents the net inhaled dose, with the
assumption of equal clearance on both inhalation days.
2.6. Statistical analysis
Statistical analysis was performed with SPSS version 17.0
(PASW Statistics, IBM Corporation, Armonk, USA). A mixed
linear model with subgroup and study visit as fixed factors,
gender and age as covariates and patient as random factor was
used to estimate the effect of the breathing mode on pharmaco-
kinetic parameters and nebulization time. In this model data were
first evaluated for the absence of a possible order effect (breathing
mode ∗ study visit interaction). Paired t-tests were used to
compare differences in eGFR, FEV1% predicted values and net
inhaled dosages. The one-sample t-test was used to compare
mean Frel to the test value of 1. One-way ANOVA was used to
test for differences between subgroups. P-values below 0.05 were
considered to be statistically significant. The guideline on the
investigation of bioequivalence [19] from the committee for
medicinal products for human use (CHMP) was used to provide a
statement about the clinical relevance of the differences between
the breathing modes. In accordance with this guideline Cmax and




Eighteen CF patients (10 males), aged 19–57 years (mean
33.9 years), were included in the study. Overall, there were no
significant differences in eGFR, FEV1% predicted and netinhaled dose between both study visits (Table 1). Only
subgroup 2 showed a significant difference in FEV1%
predicted between the two study days.
3.2. Pharmacokinetics
The individual calculated pharmacokinetic parameters are
summarized in Table 2. Mean Cmax and AUC0–24 h were
significantly increased for TIM compared to TBM for the entire
study population (P b 0.001). TIM inhalation also resulted in a
higher mean Cmax and AUC0–24 h in each subgroup, though
these differences were not always significant. Differences in
Cmax and AUC0–24 h between the three subgroups were not
statistically significant and no significant interaction effects
between study visit (day 1 or 2) and breathing mode or between
subgroup (disease severity) and breathing mode for Cmax and
AUC0–24 h were found.
Frel was 1 or higher for all patients and the mean Frel of 1.53
was significantly higher than the value of 1 (P b 0.001, 95%
CI = 1.32–1.73). Fig. 1 shows the relative increase in
tobramycin bioavailability for TIM compared to TBM inhala-
tion. In addition, mean Frel was also significantly higher than 1
in each of the three subgroups separately (Table 2). Differences
in Frel between the three subgroups were not statistically
significant.
Table 3 shows the clinical relevance of differences in Cmax
and AUC0–24 h when comparing TIM to TBM inhalation. All
noted differences in these parameters were considered to be
clinically relevant between the two breathing modes.
3.3. Nebulization time
The mean nebulization time was significantly shorter with
TIM (7.63 ± 1.66 min) compared to TBM (16.34 ± 4.09 min)
Table 2
Pharmacokinetic parameters.
Study population n = 18
Subgroup n = 6
TIM TBM P-value a
Cmax (mg/L) study population 1.22 ± 0.46 0.82 ± 0.39 b0.001
Subgroup 1 1.09 ± 0.63 0.63 ± 0.28 0.046
Subgroup 2 1.10 ± 0.42 0.73 ± 0.50 0.083
Subgroup 3 1.48 ± 0.19 1.10 ± 0.22 0.011
AUC0–24 (h·mg/L) study population 8.45 ± 2.85 5.79 ± 2.21 b0.001
Subgroup 1 7.88 ± 4.43 4.64 ± 1.89 0.057
Subgroup 2 7.80 ± 2.05 5.48 ± 2.85 0.054
Subgroup 3 9.68 ± 1.01 7.24 ± 0.88 0.004
Ctrough (mg/L) study population 0.22 ± 0.073 0.15 ± 0.052 b0.001
Subgroup 1 0.21 ± 0.12 0.13 ± 0.048 0.063
Subgroup 2 0.21 ± 0.045 0.14 ± 0.065 0.024
Subgroup 3 0.25 ± 0.029 0.19 ± 0.018 0.004
Tmax (min) study population 87.83 ± 12.54 91.00 ± 16.44 0.406
Subgroup 1 89.33 ± 13.97 86.67 ± 7.69 0.711
Subgroup 2 92.67 ± 13.56 101.00 ± 20.96 0.432
Subgroup 3 81.50 ± 8.78 85.33 ± 15.46 0.674
Frel study population 1.53 ± 0.41 b0.001
Subgroup 1 1.58 ± 0.38 0.014
Subgroup 2 1.74 ± 0.52 0.017
Subgroup 3 1.26 ± 0.13 0.004
Data are presented as mean ± sd. Pharmacokinetic parameters following
tobramycin inhalation using the I-neb nebulizer (see Table 1 for mean net
inhaled dosages). TIM = Target Inhalation Mode; TBM = Tidal Breathing
Mode; Cmax = maximum serum level; Ctrough = trough serum level, 12 h after
dose; Tmax = time to maximum serum level; AUC0–24 h = area under the
concentration–time curve from 0 to 24 h; Frel = bioavailability of TIM relative to
TBM, calculated with (AUC0–24 hTIM / AUC0–24 hTBM) × (DoseTBM / DoseTIM);
Subgroup 1 ≤ 59, 2 = 60–79, 3 ≥ 80 FEV1% predicted; FEV1 = forced
expiratory volume in the first second.
a P-values for Cmax, Ctrough, Tmax, and AUC0–24 h are derived from a linear
mixed model with study visit (day 1 or 2) and subgroup as ﬁxed factors, gender
and age as covariates and patient as random factor. P-values for Frel are
calculated with the one-sample t-test with a test value of 1.
Fig. 1. Relative increase in tobramycin bioavailability as surrogate parameter
for lung deposition when using TIM compared to TBM breathing pattern,
represented by the relative bioavailability (Frel). Every dot or square represents one
patient; dots when randomized to inhale with TBM during study visit 1 and squares
when randomized to start with TIM inhalation. Frel is the bioavailability of TIM
relative to TBM, calculated with (AUC0–24 hTIM / AUC0–24 hTBM) × (DoseTBM /
DoseTIM). TIM = Target Inhalation Mode; TBM = Tidal Breathing Mode;
AUC0–24 h = area under the concentration–time curve from 0 to 24 h.
Table 3
Clinical relevance.
Study population n = 18







TIM TBM TIM vs. TBM Difference
TIM to TBM
Cmax (mg/L) study population 1.12 0.74 1.52 (1.33–1.73) Yes
Subgroup 1 0.94 0.58 1.60 (1.27–2.02) Yes
Subgroup 2 1.01 0.63 1.61 (1.09–2.37) Yes
Subgroup 3 1.46 1.08 1.36 (1.16–1.59) Yes
AUC0–24 h (h·mg/L)
study population
7.88 5.38 1.47 (1.31–1.64) Yes
Subgroup 1 6.75 4.33 1.56 (1.25–1.95) Yes
Subgroup 2 7.52 5.00 1.50 (1.08–2.09) Yes
Subgroup 3 9.64 7.19 1.34 (1.21–1.49) Yes
Clinical relevance of differences in Cmax and AUC0–24 h when comparing TIM
to TBM breathing pattern. TIM = Target Inhalation Mode; TBM = Tidal
Breathing Mode; Cmax = maximum serum level; AUC0–24 h = area under the
time–concentration curve from 0 to 24 h; Subgroup 1 ≤ 59, 2 = 60–79,
3 ≥ 80 FEV1% predicted; FEV1 = forced expiratory volume in the first
second; CI = confidence interval.
a The difference is considered to be clinically relevant when the 90% CI for
the geometric mean ratio of a parameter does not fall completely within the
acceptance interval of 0.80–1.25 and bioequivalence cannot be concluded
(derived from the CHMP guideline on the investigation of bioequivalence [19]).
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also noted for all three subgroups (Fig. 2b). These differences
were independent from disease severity and it did not matter
whether a patient used the TIM breathing pattern during his
first or second study visit. Although no significant subgroup
effect was found, nebulization time tends to shorten with better
lung function for both TIM and TBM inhalation (Fig. 2b).Fig. 2a. Mean nebulization time for TIM and TBM breathing patterns. The
error bars represent the standard deviations. TIM = Target Inhalation Mode;
TBM = Tidal Breathing Mode.
Fig. 2b. Mean nebulization time for TIM and TBM per subgroup: 1 ≤ 59, 2 = 60–
79, 3 ≥ 80 FEV1% predicted. The error bars represent the standard deviations.
Correlation coefficients as a measure of the strength and direction of a linear
relationship between nebulization time and subgroup (lung function) are R = 0.999
and R = 0.904 for TIM and TBM breathing patterns, respectively. TIM = Target
Inhalation Mode; TBM = Tidal Breathing Mode; FEV1 = forced expiratory
volume in the first second.
752 A.J. van Velzen et al. / Journal of Cystic Fibrosis 14 (2015) 748–7544. Discussion
This study demonstrated that slow and deep inhalation (TIM)
of aerosolized tobramycin with the I-neb nebulizer resulted in
53% higher total lung deposition compared to normal tidal
breathing (TBM) in patients with CF based on pharmacokinetic
data. We have also shown that TIM inhalation reduced treatment
time by half. Finally, these results were found to be independent
from disease severity, as reflected by the patients' lung function.
The results of this study are in good agreement with recent
trials investigating other novel controlled-inhalation techniques,
in which slow and deep breathing shows to be advantageous over
spontaneous breathing [20–23].
Although pharmacokinetic data has been used before and is
considered to be a simple, rapid and cheapmethod to compare lung
deposition between inhalation devices/techniques [8,15,24,25],
there are some drawbacks to this method. Most important,
pharmacokinetics only reflect total lung deposition and relation-
ships between serum levels and regional lung exposure are not
established yet [26]. However, we think that given the poor oral
absorption and low epithelial membrane crossing of tobramycin
[15], combined with the knowledge that a slow deep breathing
pattern is beneficial for peripheral deposition [5], higher
tobramycin serum levels are indicative for higher deposition
in the peripheral airways, where conditions for absorption are
better compared to the central lung. Hence, the higher Cmax and
AUC0–24 h achieved with TIM inhalation in our study indicates
higher peripheral deposition. Although no direct relationships
between drug deposition site and clinical outcomes have beenestablished in CF yet, it is expected that peripheral targeting will
result in a higher Pseudomonas drug exposure leading to a better
anti-pseudomonal effect [2]. A recent study in children with CF
inhaling dornase alfa showed greater improvement in lung
function when peripheral deposition was targeted compared to
central airway targeting [27]. Studies with asthmatic patients also
showed that regional deposition is a better predictor of clinical
outcome than total lung deposition [28,29]. Further investigations
are necessary exploring these relationships in CF.
Cmax, Tmax and AUC are most frequently used as indirect
pharmacokinetic parameters to evaluate pulmonary drug deposi-
tion. When comparing breathing modes intra-individual, AUC is
probably the best descriptor for deposition, since the difference in
nebulization time between slow deep and normal tidal breathing
can influence Cmax and Tmax. Although the AUC0–24 h was
significantly increased for TIM compared to TBM for the entire
study population and for patients included in subgroup 3,
differences in AUC0–24 h between the breathing modes in
subgroups 1 and 2 did not reach significance (Table 2). A small
number of patients per subgroup and a relative large variation in
subgroups 1 and 2 could have contributed to this result. In
addition, the wide range of net inhaled tobramycin dosages
presumably played a role (Table 1). However, when looking at
the main outcome measure Frel, calculated from AUCs corrected
for the inhaled dosages, it was found that TIM inhalation resulted
in significant higher bioavailability, i.e., higher lung deposition,
for both the entire study population as for all subgroups.
We considered all differences in Cmax and AUC0–24 h
clinically relevant based on the accepted methods of bioequiv-
alence assessment [19] (Table 3). This implies that slow and deep
breathing results in a clinically significant higher pulmonary drug
deposition. However, whether this breathing mode truly leads to
clinically better treatment effects should be investigated in trials
with clear efficacy outcomes.
We did not find a significant difference in Tmax between the
two breathing modes. Because nebulization time with TIM was
shorter and no significant differences in dosages between the
study visits existed, we also expected Cmax to be reached earlier
when comparing to TBM inhalation. An explanation may be that
within the timeframe of this nebulization pulmonary absorption is
mainly determined by rate limited absorption kinetics [12,13].
Because of the cross-over setting in this study we expected the
intra-individual variability to be low. Indeed, of all parameters
only a significant difference in FEV1% between breathing modes
was found in patients included in subgroup 2 (Table 1). Though,
the largest absolute difference in FEV1% predicted for a patient
in this subgroup was 7%, which was not considered to be
clinically relevant. The results of this study were based on a small
study population, which is a limitation. However, a sample size of
6 to 18 patients is quite common in pharmacokinetic studies
[8,12,13,21,30–32]. Inter-patient variability in lung deposition
can be large in patients with CF [8], which makes it difficult to
extrapolate results from small trials to other patients. Heteroge-
neity in disease severity may contribute to this variability and
patients were therefore categorized in three subgroups according
to their lung function. However, no significant interaction effects
between subgroup and breathing mode were found in our study.
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could not be explained by the patients' disease severity.
This study demonstrated a 53% increase in bioavailability by
inhaling slowly. In clinical trials, serum levels are often used as a
safety measure and, therefore, recommending slow deep
tobramycin inhalation may change the safety margin. Cmax and
Ctrough stayed well below toxic limits in our study with both
breathing modes. It is important to emphasize that an off-label
device and tobramycin solution/dose were used solely to
demonstrate the potential for slow deep inhalation to improve
lung deposition in CF. Clinical trials are necessary and planned to
demonstrate the efficacy and safety of this approach. However,
since the recommended dose of the licensed tobramycin solutions
(60 to 75 mg) is lower than the dose used in this study (100 mg),
toxic serum levels are not expected in daily clinical practice.
A more than two times shorter nebulization time was attained
with slow and deep inhalation, which is in good agreement with
data from other clinical trials [7,33,34]. Since treatment burden is
considered to be high in CF patients, a shorter nebulization time
can contribute to a higher treatment adherence, better therapeutic
effect and improvement of quality of life [33,34]. The clinical
experience of TIM inhalation in CF has been evaluated in several
studies [33–35]. These studies indicate that TIM is an acceptable
and easy to use breathing mode for patients with CF at all ages.
Tobramycin can also be administered as inhalation powder
by the TOBI® Podhaler (Novartis AG, Basel, Switzerland).
Comparative studies with the conventional Pari LC Plus jet
nebulizer (PARI GmbH, Starnberg, Germany) have shown
comparable lung deposition between the powder and solution,
though, four times faster treatment times were attained with the
powder inhalation [25,36]. The average treatment time for powder
administration is approximately 4–6 min [37], which is also faster
than or similar to tobramycin TIM inhalation. However, not all
CF patients tolerate the powder formulation, since it is associated
with more local adverse events [36]. Moreover, no differences in
peripheral versus central deposition between the two formulations
were demonstrated [38]. Hence, peripheral targeting is not
improved by the use of a powder inhaler.
In conclusion, this pharmacokinetic study showed higher
tobramycin deposition following slow deep inhalation com-
pared to tidal breathing in CF patients, regardless of the disease
severity of the patient. Presumably higher peripheral deposition
is achieved with a slow deep breathing mode, which may yield
better clinical results. Slow deep inhalation also shortened
treatment time considerably. This suggests that a slow and
deep breathing mode would be beneficial for all CF patients
needing antibiotic inhalation therapy. Clinical trials investigat-
ing targeted aerosol deposition in direct relationship to efficacy
and long-term safety of tobramycin TIM inhalation in a large
cohort of CF patients are required to support these conclusions.Conﬂict of interest statements
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